目的：本文旨在评价奥曲肽联合硫酸镁治疗急性重症胰腺炎（SAP）的临床效果和安全性。方法：选取2019 年1 月至2020 年12 月在我院收治的SAP 患者70 例，按照随机数字表法分为对照组和观察组，每组35 例，对照组接受常规治疗，观察组在此基础上加用奥曲肽和硫酸镁，疗程7 天。结果：观察组患者的症状缓解、生化指标改善、炎症反应降低、胰腺并发症减少、住院时间和费用缩短均优于对照组（P<0.05）。两组患者均无严重不良反应。结论：奥曲肽联合硫酸镁治疗SAP 有效且安全，可作为一种有效的治疗方案。

Abstract: Objective: The aim of this study was to evaluate the clinical efficacy and safety of octreotide combined with magnesium sulfate in the treatment of acute severe pancreatitis (SAP). Methods: A total of 70 SAP patients admitted to our hospital from January 2019 to December 2020 were selected and divided into control group and observation group according to the random number table method, with 35 cases in each group, the control group received conventional treatment, and the observation group was treated with octreotide and magnesium sulfate for 7 days. Results: The observation group was better than the control group in terms of symptom relief, improvement of biochemical indexes, reduction of inflammatory response, reduction of pancreatic complications, shortening of hospital stay and cost (P<0.05). There were no serious adverse reactions in either  group. Conclusion: Octreotide combined with magnesium sulfate is effective and safe in the treatment of SAP, and can be used as an effective treatment regimen.